Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …

This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …

Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …

Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful
immunotherapeutic tools for combating hematological diseases confronted with pressing …

Cell therapy practices date back to the 19th century and continue to expand on
investigational and investment grounds. Cell therapy includes stem cell-and non–stem cell …

Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …

Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

Regulatory T cells (Tregs) are important for the induction and maintenance of peripheral
tolerance therefore, they are key in preventing excessive immune responses and …

Regulatory T cells (Tregs) are a small yet critical subset of CD4+ T cells, which have the role
of maintaining immune homeostasis by, for example, regulating self-tolerance, tumor …

Toxoplasmosis is caused by Toxoplasma gondii, an apicomplexan parasite that is able to
infect any nucleated cell in any warm-blooded animal. Toxoplasma gondii infects around 2 …